Randall Michael Giuffre is Director at DiaMedica Therapeutics Inc. (DMAC). They have made 7 open-market trades across 1 company since 2018, most recently 2026-01-02.
CIK 0001759822
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $669K since 2018, never a sale. Across 7 scored buys the stock is up 27.8% at ninety days, and 26.9 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| DMAC | 398,587 | $3.0M |
Shares reported on the most recent Form 4, priced at the 2026-01-06 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 71% | 71% | 71% |
| Avg Move | +4.0% | +18.3% | +27.8% |
| Alpha | +6.8% | +19.8% | +26.9% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DMAC | BUY | 2023-06-23 | 2023-06-26 | $3.91 | $254K | -11.1% | -25.1% | -42.1% |
| DMAC | BUY | 2022-12-08 | 2022-12-12 | $1.42 | $134K | +2.7% | +5.3% | +16.0% |
| DMAC | BUY | 2022-12-06 | 2022-12-08 | $1.40 | $35K | +1.4% | +10.3% | +24.6% |
| DMAC | BUY | 2022-12-01 | 2022-12-05 | $1.19 | $975 | +12.7% | +8.2% | +32.8% |
| DMAC | BUY | 2022-11-29 | 2022-12-01 | $1.20 | $136K | +16.7% | +20.3% | +43.9% |
| DMAC | BUY | 2020-11-20 | 2020-11-23 | $4.26 | $64K | +32.3% | +111.6% | +130.2% |
| DMAC | BUY | 2018-12-11 | 2018-12-11 | $4.00 | $45K | -26.7% | -2.7% | -11.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.